Donnai–Barrow syndrome

From WikiMD's Food, Medicine & Wellness Encyclopedia

Autosomal recessive - en

Donnai–Barrow syndrome (DBS) is a rare genetic disorder characterized by a range of congenital anomalies and developmental delays. It is also known as faciooculoacousticorenal syndrome (FOAR). The syndrome is named after the researchers who first described it, Margaret Donnai and Michael Barrow.

Clinical Features[edit | edit source]

Individuals with Donnai–Barrow syndrome typically present with a variety of clinical features, including:

Genetics[edit | edit source]

Donnai–Barrow syndrome is caused by mutations in the LRP2 gene, which encodes the low-density lipoprotein receptor-related protein 2. This gene plays a crucial role in the development of various tissues and organs. The syndrome is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Diagnosis[edit | edit source]

The diagnosis of Donnai–Barrow syndrome is based on clinical evaluation, family history, and genetic testing. Molecular genetic testing can confirm the presence of mutations in the LRP2 gene.

Management[edit | edit source]

There is no cure for Donnai–Barrow syndrome, and treatment is primarily supportive and symptomatic. Management may include:

  • Hearing aids or cochlear implants for hearing loss.
  • Regular ophthalmologic evaluations and interventions for ocular anomalies.
  • Monitoring and management of renal function.
  • Early intervention programs and special education services to address developmental delays.

Epidemiology[edit | edit source]

Donnai–Barrow syndrome is extremely rare, with only a few dozen cases reported in the medical literature. The exact prevalence is unknown.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]

-



Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD